Study confirms that somatic cell nuclear transfer, an alternate method of creating patient-specific pluripotent stem cells, can be used to reprogram ... to enhance biomedical research and cell therapy ...

Backed by science and real results, Swiss Medica is leading the way in regenerative stem cell therapies with personalized treatments that go beyond symptom management to restore function and quality ...

"This is an amazing first step for the potential benefits of stem cell brain therapy." These early findings, however, are "suggestive of a strong promise." "I think we can finally say that stem ...

Priothera’s immunomodulator mocravimod is an adjunctive and maintenance therapy for acute myeloid ... conjunction with allogenic hematopoietic stem cell transplantation (HSCT) to treat acute ...

Mitochondria play a crucial role in acquiring pluripotency and determining cell fate. The mitochondrial ... MET and suggests that this regulatory mode exists in early differentiation and tumor ...

Stem cells can ... Brainstorm Cell Therapeutics acquired the platform through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University.

No serious adverse events were reported during the study period, and the transplanted cells produced dopamine without forming tumors, a serious risk associated with stem cell therapy. Among the ...

It's exciting to be part of a team that works to better understand how to control stem cell behavior, which could be leveraged for therapies focused on tissue regeneration or disease treatment." ...

The University of Manchester’s technology transfer company, UMI3, negotiated the terms of the major deal with Orchard Therapeutics. If we can show that it is possible to treat single gene brain ...

While stem cell therapy holds great promise for regenerating neural tissue, it has long been hindered by inefficiencies in cell delivery and low differentiation rates. Current methods, including ...

The deal has been announced just a few days after the FDA lifted a clinical hold on a phase 1/2 trial of VX-880 – a stem cell therapy Vertex acquired through its near $1 billion acquisition of ...